%0 Journal Article
%T Vildagliptin, but not glibenclamide, increases circulating endothelial progenitor cell number: a 12-month randomized controlled trial in patients with type 2 diabetes
%A Alessandra Dei Cas
%A Eleonora Derlindati
%A Elisabetta Marchesi
%A Ivana Zavaroni
%A Michela Marina
%A Monia Cito
%A Raffaella Aldigeri
%A Riccardo C. Bonadonna
%A Rosalia Aloe
%A Valentina Ridolfi
%A Valentina Spigoni
%J Archive of "Cardiovascular Diabetology".
%D 2017
%R 10.1186/s12933-017-0503-0
%X Fewer circulating endothelial progenitor cells (EPCs) and increased plasma (C-term) stromal cell-derived factor 1¦Á (SDF-1¦Á), a substrate of DPP-4, are biomarkers, and perhaps mediators, of cardiovascular risk and mortality. Short-term/acute treatment with DPP-4 inhibitors improve EPC bioavailability; however, long-term effects of DPP-4i on EPCs bioavailability/plasma (C-term) SDF-1¦Á are unknown
%K EPC
%K SDF-1¦Á
%K DPP-4 inhibitors
%K Cardiovascular risk
%U https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5324295/